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Abstract
Introduction: Respiratory failure is a life threatening complication of Guillain Barré syndrome (GBS). There is no
consensus on the specific treatment for this subset of children with GBS.
Methods: This was a prospective randomized study to compare the outcome of intravenous immunoglobulin
(IVIG) and plasma exchange (PE) treatment in children with GBS requiring mechanical ventilation. Forty-one
children with GBS requiring endotracheal mechanical ventilation (MV) within 14 days from disease onset were
included. The ages of the children ranged from 49 to 143 months.
Randomly, 20 children received a five-day course of IVIG (0.4 g/kg/day) and 21 children received a five-day course
of one volume PE daily. Lumbar puncture (LP) was performed in 36 patients (18 in each group).
Results: Both groups had comparable age (p = 0.764), weight (p = 0.764), duration of illness prior to MV (p =
0.854), preceding diarrhea (p = 0.751), cranial nerve involvement (p = 0.756), muscle power using Medical Research
Council (MRC) sum score (p = 0.266) and cerebrospinal fluid (CSF) protein (p = 0.606).
Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group
(median 13 days, IQR 11.3 to 14.5) with p = 0.037.
Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).
A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within
four weeks after PICU discharge (p = 0.606).
There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p =
0.037), but not in the IVIG group (p = 0.132).
Conclusions: In children with GBS requiring MV, PE is superior to IVIG regarding the duration of MV but not PICU
stay or the short term neurological outcome.
The negative correlation between CSF protein values and duration of MV in PE group requires further evaluation of
its clinical usefulness.
Trial Registration: Clinicaltrials.gov Identifier NCT01306578
* Correspondence: mabayoumi66@yahoo.com
1Pediatric Intensive Care Unit, Mansoura University Children Hospital, Al-
Gomhuria Street, Mansoura 35516, Egypt
Full list of author information is available at the end of the article
El-Bayoumi et al. Critical Care 2011, 15:R164
http://ccforum.com/content/15/4/R164
© 2011 El-Bayoumi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Introduction
Guillain-Barré syndrome (GBS) is, currently, the most
common cause of acute flaccid paralysis following the
worldwide decline in incidence of poliomyelitis. Inci-
dence varies according to age, geographic areas and
diagnostic criteria used for inclusion. Annual incidence
in western countries varies from 1.1 to 1.8/100,000
population per year [1-5] with a considerably lower
annual incidence of 0.66/100,000 population per year in
each of Taiwan [6] and China [7].
GBS usually follows infection by a number of bacterial
and viral agents with Campylobacter jejuni representing
the most common preceding infection [8-11]. The syn-
drome is also reported to rarely temporally follow vacci-
nation with measles vaccine [12,13], tetanus toxoid [14],
rabies vaccine [15], oral polio vaccine [16], polysacchar-
ide meningococcal vaccine [17], measles-rubella vaccine
[18], flu vaccine [19] and hepatitis B vaccine [19].
Since the publishing of the first report of the condi-
tion by Guillain, Barré, and Strohl in 1916, GBS has
remained a clinically-diagnosed disorder. The condi-
tion is a polyneuropathy involving mainly motor but
sometimes also sensory and autonomic nerves. It starts
with rapidly progressive bilateral and relatively sym-
metric weakness in the lower limbs with diminished or
absent deep tendon reflexes. Paralysis follows an
ascending pattern involving trunk, upper limb and,
finally, bulbar muscles. There can be numbness, para-
thesia and muscle pain and tenderness. Labile blood
pressure with postural hypotension and labile heart
rate with episodes of bradycardia up to asystole rarely
occur denoting autonomic neuropathy. van Doorn et
al. categorize diagnostic features of the condition into
features required for diagnosis, including progressive
weakness in both arms and legs, and areflexia or
hyporeflexia, and features that strongly support the
diagnosis, including progression of symptoms to a
nadir over days to four weeks, relative symmetry of
symptoms, mild sensory symptoms or signs, cranial
nerve involvement, autonomic dysfunction, pain, a
high concentration of protein in CSF without increase
in cells and typical electro-diagnostic features [20].
A common, yet not an early, feature of GBS is
increased cerebrospinal fluid (CSF) protein (> 45 mg/
dL) without CSF pleocytosis (< 10 cells/mm
3), often
referred to as cytoalbuminous dissociation [21]. Electro-
myography may be used to confirm the diagnosis in the
small subset of patients where the diagnosis is not
straightforward. It is also useful to sub-classify patients
into motor axonal neuropathy and acute inflammatory
demyelinating polyneuropathy [22]. A recent study con-
ducted in Egypt on children with GBS found that acute
inflammatory demyelinating polyneuropathy, was the
most common type (76%) while, acute motor axonal
neuropathy, acute motor sensory axonal neuropathy and
unclassified forms represented 8% each [23].
Respiratory failure is one of the most serious compli-
cations of GBS. It affects 15% of children with the con-
d i t i o n[ 2 4 ] .T h ea b i l i t yt op r e d i c tt h eo c c u r r e n c eo f
respiratory failure and need for mechanical ventilation
(MV) among patients with GBS has long been a target
for neurologists and intensivists alike. Some bedside
indicators of the likelihood of requiring MV are rapid
disease progression, bulbar dysfunction, bilateral facial
weakness, or dysautonomia, inability to stand, inability
to lift the elbows or head, elevated liver enzymes and
abnormal pulmonary function test [25-27]. Electrophy-
siological evidence of demyelination was also suggested
to predict the need for endotracheal MV [28].
Treatment of GBS is a multidisciplinary effort. The
general care of the child with muscle weakness includes
regular monitoring of pulmonary and cardiovascular
function for possible involvement of respiratory muscles
and autonomic neuropathy respectively, prevention of
infection and deep vein thrombosis, pain management,
early physiotherapy, early rehabilitation once muscle
power improvement starts and psychosocial support for
the affected children and their families [20].
Specific treatment of severely affected children com-
prises intravenous immunoglobulin (IVIG) or plasma
exchange (PE). Performed on more than 200 patients
each, two large trials in the mid-1980s confirmed the
beneficial role of PE in treatment of patients with GBS
compared to the conventional treatment of the time
[29,30]. The routine use of IVIG as the first line of
treatment in GBS followed the publication of a rando-
mized controlled trial (RCT) in 1992 showing a similar,
if not a superior, effect of IVIG compared to PE [31]. A
recent systematic review of heterogeneous study popula-
tions showed there was no evidence for a better out-
come with either of the two modalities of treatment.
There is also no evidence of a beneficial effect of adding
corticosteroids to the treatment [32].
The objective of this study is to compare PE and IVIG
as a first line treatment for children with severe GBS
requiring MV regarding the duration of MV, PICU stay
and short term neurological outcome.
Materials and methods
Children with GBS admitted to the Pediatric Intensive
Care Unit (PICU) at Mansoura University Children Hos-
pital, Mansoura, Egypt, with the need for MV were pro-
spectively enrolled in the study. Cases were diagnosed
to have GBS according to clinical criteria by van Doorn
et al. [20]. Patients were eligible for inclusion if they
required MV based on the indications listed below, and
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days on enrollment. Children were not eligible for inclu-
sion if they had muscle weakness for longer than 14
days before requiring MV and if IVIG or PE was started
prior to enrollment.
All patients were ventilated using endotracheal MV.
Children were intubated if they were unable to protect
their airway, had increased work of breathing (WOB),
had PaO2 less than 70 mmHg in room air requiring
increasing FiO2,o rs h o w e dC O 2 retention. When chil-
dren were able to trigger spontaneous breathing, they
were changed to a pressure-support spontaneous venti-
lation mode with continuous positive airway pressure of
5c mH 2O. Pressure support was gradually weaned to 10
cm H2O. If secretions were manageable and airway
reflexes intact, a daily spontaneous breathing trial (SBT)
was performed using a T-piece for two hours. Patients
were extubated if SBT was successful. An SBT was
deemed successful if there was no diaphoresis, increased
WOB or apnea, tachycardia (defined by increase in the
heart rate of 40 bpm or more) and if SpO2, pH, PaO2
and PaCO2 remained close to pre-SBT values. The deci-
sions to initiate, wean and terminate MV were made
independently by the attending consultant in accordance
with and in strict adherence to the unit guidelines as
above.
Over a period of three years, from January 2007 to
December 2009, 44 children were admitted with GBS
requiring MV; 41 children fulfilled inclusion criteria and
were randomized to receive either IVIG (20 children) or
PE (21 children) for initial treatment. Randomization
was done by computer-generated random tables. IVIG
was administered in a dose of 0.4 g/kg/day for five days.
Patients in the PE group received a daily one-volume PE
for five consecutive days. The sample size yields a study
power of 86.9%.
On admission, the muscle power was recorded using
the Medical Research Council (MRC) sum score [33].
Lumbar puncture (LP) was performed in the second
week of illness in 36 out of the 41 children (18 in each
group). LP was performed at the discretion of the
attending consultant.
T h ep r i m a r yo u t c o m em e a s u r ew a st h ed u r a t i o no f
mechanical ventilation and secondary outcome measures
were length of PICU stay and ability to walk unaided
within four weeks of PICU discharge. Institutional
research ethics committee approval was granted and an
informed consent was obtained from legal guardians of
children included in the study.
Statistical analysis was performed using Statistical
Package for the Social Sciences, Version 17 (SPSS, Inc.,
Chicago, IL, USA). p-value was considered significant if
less than .05.
Results
Children in the two treatment groups were comparable
as regards base line characteristics, such as age, weight,
duration of illness prior to requiring mechanical ventila-
tion, presence or absence of preceding diarrhea, cranial
nerve affection, severity of muscle weakness on PICU
admission and CSF protein when available (Table 1).
There was a statistically insignificant better outcome
in the PE group compared to the IVIG group. Favorable
outcome was defined as the child’s ability to walk inde-
pendently for 10 meters (Grade 2 on GBS disability
score) [34] within four weeks from PICU discharge. The
post discharge management and physiotherapy were
standardized for children in the two groups. In the IVIG
Table 1 Comparison of IVIG and PE groups regarding base line variables
IVIG group (n = 20) PE group (n = 21) p-value
Age (months) 106.0 ± 22.8
(74.3 to 113.5)
96.0 ± 32.8
(65.5 to 135.0)
0.764
1
Weight (kg) 32.5 ± 7.0 (23.0 to 34.8) 29.0 ± 10.1 (20.0 to 41.5) 0.764
1
DOI (days) 9.0 ± 2.7 (7.0 to 12.0) 9.0 ± 2.8 (6.5 to 11.5) 0.854
1
Diarrhea (%)
Yes 13 (65%) 12 (57.1%) 0.751
2
No 7 (35%) 9 (42.9%)
Cranial nerve affection (%)
Yes 8 (40%) 10 (47.6%) 0.756
2
No 12 (60%) 11 (52.4%)
MRC sum score 12.0 ± 4.8 (8.5 to 15.5) 12.0 ± 5.9 (4.0 to 12.0) 0.266
1
CSF protein (mg/dL) 152.1 ± 55.7 (88.3 to 173.6) 148.4 ± 43.0 (117.5 to 166.5) 0.606
1
IVIG, intravenous immunoglobulin; PE, plasma exchange; DOI, Duration of illness prior to requiring mechanical ventilation; MRC, Medical Research Council score.
Data presented as median ± SD (interquartile range)
1 Mann Whitney test
2 Chi square test.
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of children compared to 95.2% (20/21) in the PE group
(Table 2).
Children receiving PE had a significantly shorter per-
iod of mechanical ventilation compared to those receiv-
ing IVIG. The hospital stay was shorter in the PE group
without statistical significance (Table 2).
For all patients, there was a statistically significant
negative correlation between CSF protein and duration
of mechanical ventilation (p = .024). Examining the
treatment groups separately, the significant negative cor-
relation remained for the PE group (p-value = 0.037)
and not for the IVIG group (p-value 0.132) (Table 3).
There was no significant side effect attributable to any
of the treatment modalities in any of the studied
patients.
Discussion
Respiratory failure among children with GBS is a serious
complication requiring intensive supportive treatment in
addition to the specific treatment.
The two treatment groups had no significant compli-
cations attributable to treatment intervention apart from
minor hypotension episodes responding to fluid boluses
in the PE group. This confirms the safety of both IVIG
and PE for treating children with GBS.
The results of this study suggest that PE is more useful
than IVIG as a specific treatment for the subset of chil-
dren with severe rapidly progressive GBS requiring MV.
PE is believed to act by removal of circulating autoan-
tibodies [35,36], while IVIG, among other mechanisms,
is thought to work through blocking antibody produc-
tion both in vivo [37] and in vitro [38,39]. Removal of
autoantibodies, by PE, creates a concentration gradient
between the lowered blood level and the extravascular
space forcing antibody movement from the extra to the
intra vascular space to be removed during the subse-
quent session [40]. Specific anti-ganglioside antibody
levels were recently found to be associated with disease
severity [41].
Children with severe, rapidly progressive GBS, as
those included in this study, most likely have an intense
autoantibody production with a high percentage of these
antibodies already bound to nerves on development of
respiratory failure. This might provide an explanation of
why this subset of patients preferentially benefit from
removal of already bound antibodies, PE, in comparison
to blocking antibody production, IVIG.
The clinical usefulness of this relatively small differ-
ence in the duration of mechanical ventilation between
PE and IVIG groups waits to be confirmed in a larger,
probably multi-center, study.
CSF protein was elevated in all patients (Table 3) with
no statistically significant difference between the two
treatment groups (Table 1). On post hoc analysis, there
was, however, a negative correlation between CSF pro-
tein level and duration of MV in PE but not IVIG
group. This finding supports the above explanation of a
shorter duration of MV in the PE group especially in
view of a RCT showing CSF filtration to be at least as
effective as PE for treatment of GBS [42] and the sug-
gestion of a blood-CSF barrier dysfunction in adults and
children with GBS [43].
PE group had a tendency for a shorter PICU stay, p =
0.094 with a comparable ability of children to walk
unaided within four weeks from PICU discharge (Table
2). So, despite a shorter duration of MV, there was no
difference between PE and IVIG groups regarding PICU
stay or short term neurological outcome.
T oo u rk n o w l e d g e ,t h i si st h ef i r s tr a n d o m i z e dc o n -
trolled study comparing PE and IVIG for treatment of
children with rapidly progressive GBS requiring MV. An
RCT conducted in adults with GBS showed no differ-
ence in the duration of MV in PE, IVIG and combined
treatment groups [44]. This difference can be accounted
for by differences in the age and PE protocol used.
It would have been more informative to perform an
electrophysiological study for the study children to con-
firm homogeneity of the study population. It would also
add to the understanding of these results to study
Table 2 Comparison of PICU stay and duration of mechanical ventilation in the IVIG and PE groups
PICU stay (days) Mechanical ventilation (Days) Favorable outcome
(%)
Yes No
IVIG group 16.5 ± 2.1
(15.3 to 18.8)
13.0 ± 2.1
(11.3 to 14.5)
18 (90%) 2
(10%)
PE group 15.0 ± 2.6
(13.0 to 17.0)
11.0 ± 1.5
(11.0 to 13.0)
20 (95.2%) 1
(4.8%)
p-value .094
1 0.037
1 0.606
2
IVIG, intravenous immunoglobulin; PE, plasma exchange. Data presented as median ± SD (interquartile range)
1 Mann Whitney test
2 Chi square test.
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lar design.
Conclusions
Rapidly progressive GBS necessitating MV in children
responds favorably to both IVIG and PE, with PE being
superior in regard to the duration of MV but not PICU
stay or short term neurological outcome. The finding of
a negative correlation between CSF protein values and
duration of MV in the PE group might serve as a basis
for future research aiming at a better understanding of
autoantibody kinetics during treatment of GBS.
Key messages
￿ Children with GBS requiring MV respond favor-
ably to both IVIG and PE.
￿ Using a weaning and extubation protocol, children
receiving PE had a shorter duration of MV.
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